Stockreport

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Presented updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at the 36 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer [Read more]